A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02639182|
Recruitment Status : Recruiting
First Posted : December 24, 2015
Last Update Posted : March 15, 2018
|Condition or disease||Intervention/treatment||Phase|
|Metastatic Renal Cell Carcinoma||Drug: AGS-16C3F Drug: Axitinib||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||134 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Multi-Center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma|
|Actual Study Start Date :||May 24, 2016|
|Estimated Primary Completion Date :||January 2019|
|Estimated Study Completion Date :||January 2019|
AGS-16C3F will be administered as a single 60-minute intravenous (IV) infusion once every 3 weeks.
Intravenous (IV) infusion
Active Comparator: Axitinib
Axitinib will be administered twice daily continuously, by mouth.
Other Name: Inlyta®
- Progression free survival (PFS) [ Time Frame: 24 months ]Defined as the time from the date of randomization to the earliest of documented disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1 or death from any cause.
- PFS calculated based on blinded central radiology assessment per RECIST v.1.1 [ Time Frame: 24 months ]
- Objective response rate (ORR) based on the investigator's radiographic assessment [ Time Frame: 24 months ]ORR is defined as the proportion of subjects who have a best overall response of Complete Response (CR) or Partial Response (PR)
- Duration of response (DOR) based on the investigator's radiographic assessment [ Time Frame: 24 months ]DOR is defined as the time from the date of the first response of CR/PR (whichever is first recorded) to the first date of documented progressive disease or death due to any cause.
- Overall survival (OS) [ Time Frame: 24 months ]OS is defined as the number of months from the date of randomization until the date of death from any cause.
- Disease control rate (DCR) assessed by the investigator's radiographic assessment [ Time Frame: 24 months ]DCR is defined as the proportion of subjets who have a best overall response of Complete Response (CR), Partial Response (PR), or Stable Disease (SD) with a minimum duration of 6 months.
- Safety profile assessed by Incidence of adverse events (AEs), laboratory tests, vital signs and electrocardiograms (ECG) [ Time Frame: 24 months ]Laboratory tests include hematology and chemistry. Vital signs include blood pressure, heart rate, and respiratory rate.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02639182
|Contact: Astellas Pharma Global Development, Inc.||800-888-7704 ext 5473||Astellas.firstname.lastname@example.org|
Show 31 Study Locations
|Study Director:||Associate Medical Director||Astellas Pharma Global Development, Inc.|